Efficacy and Safety of Once-Weekly Semaglutide vs Daily Canagliflozin as Add-On to Metformin in Type 2 Diabetes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Diabetes & Endocrinology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and Safety of Once-Weekly Semaglutide Versus Daily Canagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes (SUSTAIN 8): A Double-Blind, Phase 3b, Randomised Controlled Trial
Lancet Diabetes Endocrinol 2019 Sep 17;[EPub Ahead of Print], I Lingvay, AM Catarig, JP Frias, H Kumar, NL Lausvig, CW le Roux, D Thielke, A Viljoen, RJ McCrimmonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.